During this webinar, Drs. Peterson and Guralnik will discuss sarcopenia, the physiological mechanisms underlying the disease, and the current avenues of treatment and assessment that are being researched and developed for patients.

Sarcopenia is the age-related loss of muscle that causes decreased strength and functional limitations. Muscle loss occurs universally in people as we age, but some people lose muscle at an accelerated rate compared to others. While chronic disease can cause sarcopenia, it can also result from a sedentary lifestyle, hospitalizations and extended bed rest due to other conditions.
A gradual decline in muscle mass and strength begins around 30 years of age with this condition, and annual losses get larger throughout life. The self-reporting of functional difficulties to health care providers may give an indication that sarcopenia is present, but a more precise definition is needed for research and clinical use.

Efforts made in Europe and the US have used grip strength, gait speed and lean mass to define sarcopenia, but these definitions lead to large differences in prevalence rate and discordance in who is labelled as “sarcopenic”. To assess this condition, lean mass as measured by dual x-ray absorptiometry (DXA) may not accurately reflect actual muscle mass, but a new technique using dilution of deuterium-labelled creatine may prove to be superior in clinically diagnosing sarcopenia. Currently, a consensus has not been reached on the clinical outcome assessments that can be used by regulatory agencies to judge the effectiveness of drugs for sarcopenia.

A number of potential interventions are being explored to treat sarcopenia in older people, but no drugs are currently approved for this condition. The antidiabetic drug metformin shows promise in preventing many age-associated conditions, but appears to blunt the benefits of exercise on muscle. Senolytic drugs, which clear senescent cells, may improve muscle repair following injury preferentially in older individuals.

Presenters

Professor of Epidemiology and Public Health
Epidemiology and Public Health
University of Maryland School of Medicine

Dr. Jack Guralnik is currently Professor of Epidemiology and Public Health at the University of Maryland School of Medicine. He spent 25 years doing research at the National Institute on Aging and was Chief of the intramural Laboratory of Epidemiology, Demography and Biometry.

Joseph Hamburg Endowed Professor, CMB Director
Center for Muscle Biology Physical Therapy
University of Kentucky

Dr. Peterson’s research focuses on elucidation of cellular and molecular mechanisms controlling skeletal muscle structure and function. She is currently funded by the NIH and by the Department of Defense to study the role of adult stem cells in muscle maintenance and adaptation; the influence of obesity and inflammation on muscle function; muscle changes in response to blast injuries resulting in retained metal in muscle; interventions to maintain muscle health in the face of chronic disease and during aging; and strategies to improve exercise outcomes in the elderly. Her long term goal is to develop new strategies to prevent frailty and loss of functional independence.

Additional Content From American Physiological Society

Targeting Biological Aging: A New Paradigm for 21st Century Medicine

Targeting Biological Aging: A New Paradigm for 21st Century Medicine

During this webinar, Dr. Matt Kaeberlein will provide an overview of translational geroscience, which he believes will become the paradigm for the practice of medicine in the 21st century. He will also discuss recent work with one such intervention, the drug rapamycin, and its potential to enhance healthspan in companion dogs and people.
Myeloid Cells and Cardiovascular Health

Myeloid Cells and Cardiovascular Health

Dr. Matthias Nahrendorf discusses current concepts of cell supply by the hematopoietic system, highlights open questions, and describes imaging tools for studying monocytes, macrophages and their progenitors.

Related Content

Targeting Biological Aging: A New Paradigm for 21st Century Medicine

Targeting Biological Aging: A New Paradigm for 21st Century Medicine

During this webinar, Dr. Matt Kaeberlein will provide an overview of translational geroscience, which he believes will become the paradigm for the practice of medicine in the 21st century. He will also discuss recent work with one such intervention, the drug rapamycin, and its potential to enhance healthspan in companion dogs and people.
Aging and Bone Health

Aging and Bone Health

In this webinar, Dr. Joy Wu will review the pathophysiology of bone loss with aging, in particular the imbalance between bone formation by osteoblasts and bone resorption by osteoclasts. She will discuss stem cell sources of osteoblasts, anabolic signaling pathways, and targeting inflammation and senescence.